Piramal Pharma Acquires Kenalog Brand for Up to $100 Million to Strengthen Injectable Portfolio

Piramal Pharma has announced a strategic acquisition of the Kenalog brand for up to $100 million, marking a significant step in strengthening its injectable pharmaceutical offerings and supporting its global expansion strategy.

Strategic Acquisition Details

The acquisition of the Kenalog brand represents a substantial investment by Piramal Pharma in expanding its pharmaceutical portfolio. The deal, valued at up to $100 million, demonstrates the company's commitment to enhancing its presence in the injectable medications segment.

Parameter:	Details
Acquisition Value:	Up to $100 million
Brand Acquired:	Kenalog
Strategic Focus:	Injectable offerings
Objective:	Global expansion support

Portfolio Enhancement Strategy

This acquisition aligns with Piramal Pharma's broader strategy to strengthen its injectable pharmaceutical offerings. The addition of the Kenalog brand to the company's portfolio is expected to enhance its competitive position in the global pharmaceutical market.

Global Expansion Initiative

The Kenalog brand acquisition forms part of Piramal Pharma's ongoing efforts to support its global expansion objectives. This strategic move positions the company to better serve international markets and expand its pharmaceutical reach across different geographical regions.

The investment underscores Piramal Pharma's focus on building a robust injectable portfolio while pursuing growth opportunities in the global pharmaceutical landscape.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.67%	+1.45%	-11.54%	-28.15%	-35.60%	-23.97%

Piramal Pharma Limited has officially notified stock exchanges about its upcoming board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting will focus on considering and approving the unaudited financial results for both standalone and consolidated operations. The meeting covers the financial performance for the quarter and nine months ended December 31, 2025.

Meeting Parameter:	Details
Date:	Wednesday, January 28, 2026
Purpose:	Q3FY26 Unaudited Financial Results
Coverage:	Quarter and Nine Months Ended December 31, 2025
Format:	Standalone and Consolidated Results

Trading Window Closure

In accordance with regulatory requirements, Piramal Pharma Limited has implemented a trading window closure for company securities. The trading window, which commenced closure on January 1, 2026, will remain closed until January 30, 2026, both days inclusive.

Trading Window Details:	Information
Closure Start Date:	Thursday, January 1, 2026
Closure End Date:	Friday, January 30, 2026
Duration:	Both days inclusive
Reason:	Board meeting for financial results

Regulatory Compliance

The company has formally notified both major Indian stock exchanges about the scheduled board meeting. BSE Limited, where the company trades under scrip code 543635, and National Stock Exchange of India Limited, where it trades under the symbol PPLPHARMA, have been informed through official communication dated January 16, 2026.

Company Secretary Tanya Sanish signed the official intimation, ensuring compliance with SEBI Listing Regulations. The notification follows standard corporate governance practices for listed pharmaceutical companies in India, providing investors and stakeholders with advance notice of material financial disclosures.